License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended September 30,				Nine months ended September 30,
Partner	Drug or Drug Candidate	2017		2016		2017		2016
Eli Lilly and Company	NKTR-358	$	127,553	$	—	$	127,553	$	—
AstraZeneca AB	MOVANTIK® and MOVANTIK® fixed-dose combination program		—		3,000		4,600		31,000
Amgen, Inc.	Neulasta®		1,250		1,250		3,750		3,750
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		357		357		1,072		1,072
Daiichi Sankyo Europe GmbH	ONZEALDTM (NKTR-102)		216		216		647		3,474
Baxalta Incorporated	ADYNOVATE®		312		336		357		648
Roche	MIRCERA®		—		1,929		—		5,771
Other			1,424		1,285		4,049		5,114
License, collaboration and other revenue		$	131,112	$	8,373	$	142,028	$	50,829